Viewing Study NCT00229723



Ignite Creation Date: 2024-05-05 @ 12:02 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00229723
Status: COMPLETED
Last Update Posted: 2009-08-04
First Post: 2005-09-28

Brief Title: IRESSA Gefitinib With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage IIIIV Non-Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A Phase 2 Randomised Double-Blind Placebo-Controlled Multicentre Comparative Study of Gefitinib 250 mg or 500 mg IRESSA Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreated Unresected Late Stage IIIIV Non-Metastatic Head and Neck Squamous Cell Carcinoma
Status: COMPLETED
Status Verified Date: 2009-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy X-rays plus chemotherapy cisplatin in terms of local disease control progression-free rate at 2 years
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
D7919C00706 None None None
EudraCT number 2004-000358-21 None None None